


Overview of available adenovirus packaging constructs and assessment of their capacity to transform primary kidney cells



\*average of 5 plates 21 days after transelection

FIG. 6

Western blotting analysis of A549 clones transfected with pIG.E1A.NEO and PER clones (HER cells transfected with pIG.E1A.E1B)




FIG. 7

# Southern blot analyses of 293, 911 and PER cell lines




FIG. 8

Transfection efficiency of PER.C3, PER.C5, PER.C6 and 911 cells. Cells were cultured in 6-well plates and transfected (n=2) with 5  $\mu$ g pRSV.lasZ by calcium-phosphate co-precipitation. Forty-eight hours later the cells were stained with X-GAL. The mean percentage of blue cells is shown.




FIG. 9

#### Construction of pMLP1.TK




FIG. 10

New recombinant adenoviruses and packaging constructs without sequence overlap






FIG. IIA

Packaging system based on primary cells

New recombinant adenoviruses and packaging constructs without sequence overlap



Packaging system based on established cell lines: transfection FIG. with E1a and selection with G418






FIG. 13

# Replication of Adenovirus




FIG. 14

The potential hairpin conformation of a single—stranded DNA molecule that contains the HP/asp sequences used in these studies. Restriction with the restriction endonucleases <code>Asp7181</code> of plasid pICLHa, containing the annealed oligonucleotide pair HP/asp1 en HP/asp2 will yield a linear double—stranded DNA fragment. In cells in which the required adenovirus genes are present, replication can initiate at the terminus that contains the ITR sequence. During the chain elongation, the one of the strands will be displaced. The terminus of the single—stranded displaced—strand molecule can adopt the conformation depicted above. In this conformation the free 3'—terminus can serve as a primer for the cellular and/or adenovirus DNA polymerase, resulting in conversion of the displaced strand in a double—stranded form.

5'-GTACACTGACCTAGTGCCGCCCGGGCA ||||||||||||| A 3'-GATCACGGCGGCCCGA

FIG. 15




FIG. 16




FIG. 17




FIG. 18




FIG. 19

#### Cloned adenovirous fragments




FIG. 20

### Adapter plasmid pAd5/L420-HSA




FIG. 21

## Adapter plasmid pAd5/CLIP





FIG. 22



## Minimal adenovirus vector pMV/L420H





FIG. 24








FIG. 26A





Average percentage CPE efficiency: 86 %

FIG. 27

T T '	nsert kh	
	<b>ئ</b>	•
7	rene	147)

ceNOS

hTERT


hTERT D712A
lacZ
hCAT1
CLuc
SOD3
MAX1
hVEGF121
hVEGF121
hVEGF121


**ANG1-7** 


28 FIG.

Average titer  $3 \pm 0.7 \times 10^9 \text{ pfu/ml}$ 0.8

3.6 3.5 3.5 3.2 2.2 2.0 1.7 1.4 .510 .511 .434












FIG. 32








FIG. 34B







FIG. 34C















FIG. 34G














FIG. 34M

Relative amounts of wells with CPE after transfection of PER.C6/E2A cells with pCLIP—LacZ and the adapter plasmid pIPspAdapt2.

Transfection of pIPspAdapt2 to PER.C6/E2A







FIG. 34N









FIG, 36B

EXAMPLE 21 384 WELL PLATE IN PROGRESS



Medium changed 7 days after transfection



**FIG. 38A** 

Medium not changed




FIG. 38B

Propagation 7 days after transfection








FIG. 38C












>











Figure 47 Infection of human primary pre-adipocytes








Figure 49


Adipocyte differentiation Primary human mesenchymal stem cells



Adipocyte differentiation Mouse mesenchymal stem cell line C3H10T1/2



H5-24: adenoviraly mediated expression of CIDEB does not induce any cell death



H5-1 DNA sequence (SEQ ID NO:12)

1	GCCCACGCGT	CCGGTTTTCT	ACTTTGCCAC	AGATTATCTT	GTACAGCCTT	TTATGGACCA
61	ATTAGCATTC	CATCAATTTT	ATATCTAGCA	TATTTGCGGT	TAGAATCCCA	TGGATGTTTC
121	TTCTTTGACT	ATAACAAAAT	CTGGGGAGGA	CAAAGGTGAT	TTTCCTGTGT	CCACATCTAA
181	CAAAGTCAAG	ATTCCCGGCT	GGACTTTTGC	AGCTTCCTTC	CAAGTCTTCC	TGACCACCTT
241	GCACTATTGG	ACTTTGGAAG	GAGGTGCCTA	TAGAAAACGA	TTTTGAACAT	ACTTCATCGC
301	AGTGGACTGT	GTCCCTCGGT	GCAGAAACTA	CCAGATTTGA	GGGACGAGGT	CAAGGAGATA
361	TGATAGGCCC	GGAAGTTGCT	GTGCCCCATC	AGCAGCTTGA	CGCGTGGTCA	CAGGACGATT
421	TCACTGACAC	TGCGAACTCT	CAGGACTACC	GTTACCAAGA	GGTTAGGTGA	AGTGGTTTAA
481	ACCAAACGGA	ACTCTTCATC	TTAAACTACA	CGTTGAAAAT	CAACCCAATA	ATTCTGTATT
541	AACTGAATTC	TGAACCTTTC	AGGAGGTACT	GTGAGGAAGA	GCAGGCACCA	GCAGCAGAAT
601	GGGGAATGGA	GAGGTGGGCA	GGGGTTCCAG	CTTCCCTTTG	ATTTTTTGCT	GCAGACTCAT
661	CCTTTTTAAA	TGAGACTTGT	TTTCCCCTCT	CTTTGAGTCA	AGTCAAATAT	GTAGATTGCC
721	TTTGGCAATT	CTTCTTCTCA	AGCACTGACA	CTCATTACCG	TCTGTGATTG	CCATTTCTTC
781	CCAAGGCCAG	TCTGAACCTG	AGGTTGCTTT	ATCCTAAAAG	TTTTAACCTC	AGGTTCCAAA
841	TTCAGTAAAT	TTTGGAAACA	GTACAGCTAT	TTCTCATCAA	TTCTCTATCA	TGTTGAAGTC
901	AAATTTGGAT	TTTCCACCAA	ATTCTGAATT	TGTAGACATA	CTTGTACGCT	CACTTGCCCC
961	AGATGCCTCC	TCTGTCCTCA	TTCTTCTCTC	CCACACAAGC	AGTCTTTTTC	TACAGCCAGT
1021	AAGGCAGCTC	TGTCGTGGTA	GCAGATGGTC	CCATTATTCT	AGGGTCTTAC	TCTTTGTATG
1081	ATGAAAAGAA	TGTGTTATGA	ATCGGTGCTG	TCAGCCCTGC	TGTCAGACCT	TCTTCCACAG
1141	CAAATGAGAT	GTATGCCCAA	AGACGGTAGA	ATTAAAGAAG	AGTAAAATGG	CTGTTGAAGC
1201	ААААААААА	AAAAA				

#### H5-24 DNA sequence (SEQ ID NO:14)

1	GTCGACCCAC	<b>GCGTCCG</b> CGC	CTGCAGAAGG	TTGACTGCGT	GGTAGGGGGC	CCAGAGCAAG
61	CCGAAGGCAA	GCACGATGGC	GCTCACCAGC	CGGCCCACCC	GCGCCCCGTG	CCGCCCGGAG
121	CCCCAGCGGG	CGCCCGCAG	CCGTGCCAGC	GTCACGCTGT	AGCAGCCGAG	CATCAGCCCG
181	AAAGGAAGCA	CGAAAGCGGT	GGCGGTAGAC	GGCGGCCGGG	ACGGCGAGCA	ACAGGGCGGC
241	CAGCCAGACC	GCCAGCAGCA	GGCGGCGGGC	CAGGGCCGGG	CTGCGCAGCC	GAGGCGCCAG
301	GAAGGGGCGG	GTGACTGCGA	GGCAGCGCTG	CAGGCTGAGC	AGGCCGGTGA	GCAGCACGCT
361	GGCGTACATG	CTGAGCGCGC	ACACGTAGTA	CACCGCCTTG	CAGCCCGCCT	GGCCCAGCGG
421	CCAGGCCTGC	CGGGTCAGGA	AGGCCACAAA	GAGCGGCGTG	AGCAGCAGCA	CCGCGCCGTC
481	GGCCAGCGCC	AGGTGCAGCA	CAAGCGTGGC	CGCCAGCGGT	CGCCCCGTG	CAGGCCGCCA
					CCCAGCAGCG	
					AGCAGTGTCT	
					ACAGAAAAAA	
721	CTGGGGGACC	CCTACAAGGA	TCCTTGGCAG	GAAAGCAGGG	ATTGTGTTCA	TTTGAGGGTT
					TCACGGCTGC	
					CCATCAAAGG	
					AGAAAAGTGA	
					CAGAGCAGTG	
					GGAGAGAACC	
					CCTCTCAGCT	
					TGGACGGAGG	
					CAAGCGGACC	
					ATTGGAGACC	
					AGTGGACAGT	
					GTCTGGTCAG	
					GAGGCCCAAG	
						TTTGGCAGCC
						CAAGGACTTG
						CAAGGCCTGG
						GCTGAGCAGT
						CCCCAGAATC
						TGCAGACAGT
						GACAGAACCT
						TGTTCTTTCC
						TCCCCCAGGC
						CCTGTCCCTA
						GTCTTCATAC
			AAACATTTC	C AATAAAATA	A TCAAATATTI	AAAAAAAAA :
2221	AAAAAAAGGG	CGGCCGC				

H5-24 ORF4 Amino Acid sequence (SEQ ID NO: 71)

MEYLSALNPSDLLRSVSNISSEFGRRVWTSAPPPQRPFRVCDHKRTIRKGLTAAT RQELLAKALETLLLNGVLTLVLEEDGTAVDSEDFFQLLEDDTCLMVLQSGQSWS PTRSGVLSYGLGRERPKHSKDIARFTFDVYKQNPRDLFGSLNVKATFYGLYSMS CDFQGLGPKKVLRELLRWTSTLLQGLGHMLLGISSTLRHAVEGAEQWQQKGRL HSY

H5-24 Segment 1 of BLTR2 DNA sequence (SEQ ID NO: 15)

18 CGC CTGCAGAAGG TTGACTGCGT GGTAGGGGGC CCAGAGCAAG
61 CCGAAGGCAA GCACGATGGC GCTCACCAGC CGGCCCACCC GCGCCCGTG CCGCCGGAG
121 CCCCAGCGGG CGCCCCGCAG CCGTGCCAGC GTCACGCTGT AGCAGCCGAG CATCAGCCCG
181 AAAGGAAGCA CGAAAGCGGT 200

#### H5-24 Segment 2 DNA sequence (SEQ ID NO: 16)

		198 GGT	GGCGGTAGAC	GGCGGCCGGG	ACGGCGAGCA	ACAGGGCGGC
241	CAGCCAGACC	GCCAGCAGCA	GGCGGCGGGC	CAGGGCCGGG	CTGCGCAGCC	GAGGCGCCAG
301	GAAGGGGCGG	GTGACTGCGA	GGCAGCGCTG	CAGGCTGAGC	AGGCCGGTGA	GCAGCACGCT
361	GGCGTACATG	CTGAGCGCGC	ACACGTAGTA	CACCGCCTTG	CAGCCCGCCT	GGCCCAGCGG
421	CCAGGCCTGC	CGGGTCAGGA	AGGCCACAAA	GAGCGGCGTG	AGCAGCAGCA	CCGCGCCGTC
481	GGCCAGCGCC	AGGTGCAGCA	CAAGCGTGGC	CGCCAGCGGT	CGCCCCCGTG	CAGGCCGCCA
541	GCCCGCCAAG	CTCCACACCA	CGAAGCCGTT	GCCAGGCAGC	CCCAGCAGCG	CCGCCAGCAG
601	CAGGAAGGCT	GTGCCTGTGG	CCCGCGAAGT	CTTCCAGCTC	AGCAGTGTCT	CGTTCCCTGG
	GGGACGGTAG					

# DNA Sequence Comparison of H5-24 Segment 1 (SEQ ID NO: 15) with BLTR2 Antisense DNA sequence

SEQ ID NO:15		cgcctgcagaaggttgactgcgtggtagggggcccagagcaagccgaaggcaagcacgat //
BLTR2	2455	cgcctgcagaaggttgactgcgtggtagggggcccagagcaagccgaaggcaagcacgat 2396
SEQ ID NO:15		ggcgctcaccagccggcccacccgcgccccgtgccgccggagccccagcgggcgccccg 137
BLTR2	2395	ggegeteaceageeggeecaceeggeecegtgeeggageeceagegggegeeeeg 2336
SEQ ID NO:15		cagccgtgccagcgtcacgctgtagcagccgagcatcagcccgaaaggaagcacgaaagc 197
BLTR2	2335	cagccgtgccagcgtcacgctgtagcagccgagcatcagcccgaaaggaagcacgaaagc 227
SEQ ID NO:15	198	ggt 200
BLTR2	2275	ggt 2273

# DNA Sequence Comparison of H5-24 Segment 2 (SEQ ID NO: 16) with BLTR2 Antisense DNA sequence

SEQ ID NO:16	198	ggtggcggtagacggccgggacggcgagcaacagggcggccagcca	257
BLTR2	2195	ggtggcggtagacggcgggccgggacggcaacagggcggccagcca	2136
SEQ ID NO:16	258	gcaggcggcgggccagggccgggctgcgcagccgaggcgccaggaaggggcgggtgactg	317
BLTR2	2135	gcaggcggcgggccagggctgggctgcgcagccgaggcgaagggaagggggggtgactg	2076
SEQ ID NO:16	318	cgaggcagcgctgcaggctgagcaggccggtgagcagcacgctggcgtacatgctgagcg 	377
BLTR2	2075	cgaggcagcgctgcaggctgagcaggccggtgagcagcacgctggcgtacatgctgagcg	2016
SEQ ID NO:16	378	cgcacacgtagtacaccgccttgcagcccgcctggcccagcggccaggcctgccgggtca	437
BLTR2	2015		1956
SEQ ID NO:16		ggaaggccacaaagagcggcgtgagcagcagcaccgcgccgtcggccagcgccaggtgca	
BLTR2	1955	ggaaggccacaaagagcggcgtgagcagcagcaccgcgccgtcggccagcgccaggtgca	1896
SEQ ID NO:16	498	gcacaagcgtggccgccagcggtcgccccgtgcaggccgccagcccgccaagctccaca	557
BLTR2	1895		1836
ano in No ic	550		617
SEQ ID NO:16		ccacgaagccgttgccaggcagccccagcagcagcagcaggaaggctgtgcctg	
BLTR2	1835	ccacgaagccgttgccaggcagccccagcagcagcagcaggaaggctgtgcctg	1776
SEQ ID NO:16	618	tggcccgcgaagtcttccagctcagcagtgtctcgttccctgggggacggtagcagaccg	677
BLTR2	1775	tggcccgcgaagtcttccagctcagcagtgtctcgttccctggggggacggtagcagaccg	1716
SEQ ID NO:16	678	acatecttetgggeetacagg 698	
BLTR2			
THIKE	1/13	acaccccccaggcccacagg 1033	